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| BACKGROUND
The definition of acute PE is the presence of filling defect of the pulmonary artery or some of its branches by thrombus originated in situ or dislodged from venous vasculature. The time limit of acute PE from symptoms to diagnosis and treatment is previously set as 14 days according to the thrombolytic time window. However, in 2014 ESC Guidelines, 1 Pulmonary embolism severity index (PESI) was used for prediction of early (in-hospital or 30-day) outcome in patients with acute PE. PESI Class III to V indicates moderate to very high 30-day mortality risk; simplified PESI (sPESI) ≥1 point(s) indicates high 30-day mortality risk. So we set the time limit of acute PE as 30 days in this study. The time limit of sub-acute PE from symptoms to diagnosis and treatment is set as 3 months in 2014 ESC Guidelines. 1 Accordingly, the time limit of chronic PE from symptoms to diagnosis and treatment is set as more than 3 months. Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic PE. The diagnosis of CTEPH is based on the follow findings obtained after at least 3 months of effective anticoagulation: mean pulmonary arterial pressure ≥25 mm Hg, with pulmonary arterial wedge pressure ≤15 mm Hg; at least one (segmental) perfusion defect detected by perfusion lung scan, or pulmonary artery obstruction seen by CT angiography or conventional pulmonary cineangiography. The cumulative incidence of symptomatic CTEPH secondary to acute PE was reported 3.8% at two years in a prospective, long-term, follow-up study. 2 In a Chinese prospective study including 614 acute PE patients, the cumulative incidence of CTEPH was 1.3% at 2 years, and 1.7% at 3 years. 3 However, in real world, patients diagnosed with PE for the first time were usually composed of acute PE, sub-acute PE and chronic PE, and the cumulative incidence of CTEPH in this cohort were still unknown. The risk factors for CTEPH are different from those risk factors of acute PE. The risk factors for CTEPH after acute PE are reported in a study as follows: ventriculo-atrial shunts, infected pacemakers, splenectomy, previous venous thromboembolism (VTE), recurrent VTE, blood groups other than O, lupus anticoagulant/antiphospholipid antibodies, thyroid replacement therapy and a history of malignancy. 4 Another study suggested that an elevated level of Factor VIII and two thrombophilic factors related with recurrent thrombosis are associated with CTEPH. 5 A Chinese study reported that a history of lower-limb varicose veins, Pulmonary artery systolic pressure (SPAP) >50 mmHg at initial PE episode, intermediate-risk PE, and CT obstruction index over 30% at 3 months after acute PE were associated with increased risk of CTEPH. 3 However, in real word, risk factors of CTEPH in PE patients diagnosed for the first time were still unknown. The purpose of this prospective, long-term, follow-up study was to assess the incidence of symptomatic CTEPH in a large series of consecutive patients with symptomatic PE diagnosed for the first time and adequate anticoagulant treatment no less than 3 months. We also evaluated potential risk factors for CTEPH in these unspecific PE patients.
| METHODS

| Study design and patients
Consecutive patients visiting Xijing Hospital, which serves as a primary referral center, underwent a standardized diagnostic workup for PE. Patients without prior PE or VTE, diagnosed with symptomatic PE for the first time were included in the cohort study, which comprised of acute PE, sub-acute PE and chronic PE. In the chronic PE sub-group of the cohort, echocardiography was employed to exclude those patients already meeting those criteria of RV hypertrophy and dysfunction, including RV thickening, dilation and/or an increased end-diastolic RV/LV diameter ratio (in most studies, the reported threshold value was 0.9 or 1.0); hypokinesia of the free RV wall; increased velocity of the tricuspid iregurgitation jet; or combinations of the above. On computed tomographic (CT) angiography (four-chamber views of the heart), RV dysfunction is defined as an increased end-diastolic RV/LV (left ventricular) diameter ratio (with a threshold of 0.9 or 1.0). We defined those patients as suspected CTEPH, and these patients were excluded from this study. Patients were also excluded if they were geographically inaccessible for follow-up, or declined to participate in the study. The Xijing institutional review board approved the study protocol, and each patient provided written informed consent.
The severity of the pulmonary embolism at presentation were stratified as high risk Follow-up was performed prospectively at 3 months, 6 months, 12 months and at least every 6 months after the first year and in total up to 3 years. The minimum period of follow-up was one year. For patients who died during follow-up, the date and cause of death were documented. An independent, expert committee assessed all study outcomes ( Figure 1 ).
| Procedures
Patients who had unexplained persistent dyspnea on exertion or at rest after more than 3 months of anticoagulation treatment during follow-up were considered potential CTEPH. These patients initially underwent transthoracic echocardiography. If the tricuspid regurgitation velocity was more than 2.8 m/s, patients underwent ventilation-perfusion lung scanning and/or computer tomography pulmonary angiography to confirm the existence of thromboembolism, and right heart catheterization to confirm the diagnosis of pulmonary hypertension. CTEPH was confirmed when all the following criteria were included: duration of anticoagulation was more than 3 months; the mean pulmonary-artery pressures exceeded 25 mmHg; the pulmonary arterial wedge pressure was normal; and there was evidence of pulmonary embolism. 6 Data on all patients with suspected CTEPH were reviewed by an expert committee. The severity of functional impairment of CTEPH was classified according to the WHO functional classification for pulmonary hypertension. 
| Classification of pulmonary embolism and risk factors
Patients were classified as PE with secondary risk factors (recent trauma, fracture, surgical intervention, hospitalization, pregnancy, active cancer, long term immobilization and the use of oral contraceptives or hormone-replacement therapy) or primary risk factors (deficiency of antithrombin, protein C, or protein S; coagulation factor abnormality; mutation in the factor V Leiden or prothrombin gene; the presence of lupus anticoagulants, and hyperhomocysteinemia). 1 All other patients with an unknown reason were classified as idiopathic PE. 1 The following potential risk factors for CTEPH were considered: age, sex, time from symptoms to treatment of PE, risk stratification, location of embolism, and PE related risk factors. Patients with suspected recurrent PE during the study underwent objective testing.
| Statistical analysis
Kaplan-Meier method was used to estimate the cumulative incidence of CTEPH among patients who entered the study with diagnosis of PE for the first time without prior VTE. In addition, potential risk factors for CTEPH were evaluated in the entire cohort with the use of univariate logistic-regression analysis. Then, all variables with a univariate level of
The study protocol diagram. Consecutive patients diagnosed with symptomatic PE for the first time were included in the cohort study. Patients were excluded if they were prior PE, VTE or suspicious of CTEPH. Follow-up was performed prospectively at 3 months, 6 months, 12 months and at least every 6 months after the first year and in total up to 3 years. Patients who had unexplained persistent dyspnea on exertion or at rest after more than 3 months of anticoagulation treatment during follow-up were considered potential CTEPH, and underwent transthoracic echocardiography. If the tricuspid regurgitation velocity was more than 2.8 m/s, patients underwent ventilation-perfusion lung scanning and/or computer tomography pulmonary angiography to confirm the existence of thromboembolism, and right heart catheterization to confirm the diagnosis of pulmonary hypertension. An independent, expert committee assessed all study outcomes
significance of less than 0.1 were included in a backward, stepwise multivariate logistic-regression model. All calculations were performed with the use of SPSS, version 16.0, software.
| RESULTS
We included 239 consecutive patients with PE diagnosed for the first time and in accordance with the inclusion and exclusion criteria for long term follow-up. The median follow-up was 32.6 months, and the maximum was 5 years. No patients were lost to follow-up.
| Clinical characteristics for PE patients
Of the 239 patients, 163 (68.2%) had one or more primary risk factors for PE, and 76 (31.8%) had no primary risk factors ( 
| Cumulative Incidence of CTEPH
During follow-up of the 239 patients, 15(6.28%) died. 2(0.84%) died as a direct consequence of thrombolysis, 9(3.77%) died as a direct consequence of lung cancer or other malignant disease, 3(1.26%) died due to severe pneumonia, and 1(0.42%) died of chronic right heart failure due to CTEPH. 3(1.26%) patients were found to have recurrent PE during follow-up. Kaplan-Meier analysis showed that the cumulative incidence of CTEPH in PE patients diagnosed for the first time was 11.2% at 3 months, 12.2% at 6 months, 12.7% at 1 year, 13.4% at 2 years, and 14.5% at 3 years ( Figure 2) . Among 32 CTEPH patients, Only 9.4% of CTEPH patients developed from acute PE, and 90.6% from sub-acute and chronic PE according to history and radiological review.
| Risk factors for CTEPH
Of the 32 patients with confirmed diagnosis of symptomatic CTEPH, 29 had one or more primary risk factors, only 3 had no primary risk factors ( (Table 3 ). There were no significant demographic and clinical difference between symptomatic CTEPH patients with primary risk factors and those without primary risk factors for PE (Table 3) . Risk factors for CTEPH were analyzed between patients with and without CTEPH. In the univariate model, female gender, time from symptoms to treatment of PE≥1 month, intermediate or high risk PE, segmental and sub-segmental embolism, hyperhomocystinemia and PE with primary risk factors were related with high risk for CTEPH ( 
| DISCUSSION
The epidemiologic data regarding the incidence of CTEPH is reported at least 5 per million inhabitants per year, 7 however, the proportion of patients who develop CTEPH after acute PE varies in different studies. 8, 9 The incidence of CTEPH in this study is much higher than that reported in previous studies so far. The reasons are as follows: 1) The previous reported incidence of CTEPH are only for acute PE. However, in real word, not all the PE patients diagnosed for the first time are acute PE. These PE patients are usually composed of acute PE, sub-acute PE and chronic PE. The sub-group of chronic PE can't be diagnosed CTEPH, if they have no signs of RV remodeling and dysfunction, but chronic PE patients can more easily develop CTEPH in the follow-up compared with acute PE. Time from symptoms to treatment of PE is about 13.29 ± 13.58 months in CTEPH patients (Table 3) . Among 32 CTEPH patients, Only 9.4% of CTEPH patients developed from acute PE, and 90.6% from sub-acute and chronic PE according to history and radiological review. 2) A definite diagnosis of CTEPH should be made only after no F I G U R E 2 Cumulative incidence of symptomatic CTEPH after first diagnosis of pulmonary embolism in the population of northwest China. The cumulative incidence of CTEPH was 11.2% at three months, 12.7% at one year, 13.4% at two years, and 14.5% at three years
less than 3 months of anticoagulation treatment according to 2015 clinical guidelines. 6 In this study, 4 patients diagnosed CTEPH confirmed by right heart catheterization at 3 months follow up were prescribed standard anticoagulation and PDE-5 inhibitors for long term treatment. After more than 6 months (1 patient) or 1 year (3 patients) of anticoagulation and PDE-5 treatment, V/Q scan reported thrombus dissolved, and echocardiography reported normal RV structure and function. However, we can't exclude these 4 patients from statistical analysis according to the study design. This clinical phenomenon demonstrated that the current diagnostic criteria for CTEPH could have missed some critical clinical parameters, and need to be modified in the future to improve the precision diagnosis of CTEPH. All available evidence today indicates that CTEPH is primarily caused by venous thromboembolism, and a misguided vascular remodeling process also contributes to major vessel and small vessel obliteration. 5, 10 Risk factors for CTEPH are different from those for PE, 11 and varied in different studies. 12, 13 The differences of risk factors in different studies were mainly due to the variation in the patient population, treatment regimen and CTEPH diagnostic criteria. Various hereditary and acquired risk factors are associated with PE. In this study, one very interesting finding is the unusually high prevalence of hypercoagulable disorders such as protein C (20.45%), S (20.33%) and ATIII (18.79%) deficiency, factor Ⅷ increase (26.3%) in this cohort. Hyperhomocysteinemia was found in 55.37% PE patients. Also, 90.6% of the CTEPH patients had these primary PE related risk factors. This means that primary risk factors of PE play a key role in the development of CTEPH.
In our study, time from symptoms to treatment of PE ≥1 month was associated with an increased risk of CTEPH. 29 (90.6%) CTEPH patients had delayed treatment of PE more than 1 month; on the other hand, the proportion of delayed treatment patients (44.9%) decreased dramatically in non-CTEPH group (Table 4) . This means that most of the acute PE cannot be identified promptly and cannot be treated properly. To improve the diagnostic and treatment skill of acute PE will significantly reduce the incidence of CTEPH.
In this study, we found that segmental and sub-segmental embolism were associated with an increased risk of CTEPH. This might have the same meaning as the delayed diagnosis and treatment, which can cause the organization of thrombus in the distal pulmonary arteries. Intermediate or high risk PE, and PE related primary risk factors associated with an increased risk of CTEPH are the same as those in previous studies.
Our findings could bring several changes for the future management of PE in clinical practice. First, PE diagnosed for the first time is usually composed of acute PE, sub-acute PE and chronic PE. Chronic PE is much more susceptible to CTEPH. It will decrease the incidence of secondary CTEPH to improve the skill of diagnosis of acute PE and provide efficacious treatment. Second, for those patients with segmental and sub-segmental embolism, proper, long-term anticoagulation treatment and intensive follow up should be provided in order to prevent secondary pulmonary hypertension. This sub-group of PE patients might have the organization of thrombus in the distal pulmonary arteries. Third, for those patients with intermediate or high risk PE and PE related primary risk factors, intensive follow up and increasing awareness for secondary CTEPH should be provided to achieve early diagnosis of CTEPH.
| CONCLUSIONS
In conclusion, CTEPH is a relatively common and serious complication of PE diagnosed for the first time, which is composed of acute PE sub-acute PE and chronic PE. In this study, time from symptoms to treatment of PE ≥1 month, intermediate or high risk PE, segmental and sub-segmental embolism, and PE related primary risk factors were significantly associated with an increased risk of CTEPH. To improve the skill of diagnosis of acute PE and provide proper and longterm anticoagulation treatment and intensive follow up could decrease the incidence of CTEPH.
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